Protalix BioTherapeutics (PLX) EBT (2010 - 2026)

Protalix BioTherapeutics has reported EBT for 17 years, with the latest figure at $4.9 million in Q2 2026.

• On a quarterly basis, EBT rose 635.25% year-over-year to $4.9 million in Q2 2026; TTM through Jun 2026 was $23.5 million, a 85.69% increase from a year earlier, with the FY2025 full-year figure at -$5.6 million, down 164.44% from the prior year.
• EBT was $4.9 million for Q2 2026 at Protalix BioTherapeutics, down from $21.1 million in the prior quarter.
• The five-year high for EBT was $21.1 million in Q1 2026, with the low at -$5.3 million in Q2 2022.
• Average EBT over 5 years is $1.7 million, with a median of -$2.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT soared 1768.35% in 2024, then plunged 140.26% in 2025.
• Over 5 years, EBT stood at -$3.2 million in 2022, then soared by 119.78% to $635000.0 in 2023, then jumped by 1768.35% to $11.9 million in 2024, then slumped by 140.26% to -$4.8 million in 2025, then surged by 201.76% to $4.9 million in 2026.
• The last three EBT figures came in at $4.9 million (Q2 2026), $21.1 million (Q1 2026), and -$4.8 million (Q4 2025), per Business Quant data.